Resolutions at the Annual General Meeting 2016
At the Annual General Meeting of RaySearch Laboratories AB (publ) held on May 17, 2016, the following resolutions were adopted.
It was resolved that a dividend for the fiscal year 2015 amounting to SEK 0.25 per share be paid out to the shareholders. The remaining accumulated profit, amounting to SEK 99,961,554.74, was brought forward and balanced in the new accounts.
The Annual General Meeting adopted the balance sheets and income statements and discharged the members of the Board and the CEO from personal liability.
It was resolved to adopt the guidelines for remuneration to senior executives proposed by the Board, to apply until the close of the Annual General Meeting 2017.
It was resolved that remuneration to Board members who do not receive a salary from any Group company, shall amount to a total of SEK 840,000 for the period extending to the close of the next Annual General Meeting, of which SEK 480,000 will be paid to the Chairman and SEK 180,000 to each of the Board members elected by the Annual General Meeting, who do not receive a salary from any Group company.
It was resolved that the Auditor’s fees be paid in accordance with current approved invoicing.
It was resolved to re-elect Carl Filip Bergendal, Erik Hedlund, Johan Löf and Hans Wigzell as Board members of the company and to re-elect Erik Hedlund as Chairman of the Board.
It was resolved to re-elect the auditing firm Ernst & Young as Auditors, with the authorized public accountant Per Hedström as auditor in charge.
It was resolved to authorize the Board to resolve on new issues of Series B shares and/or issues of convertible debt instruments, on one or several occasions up until the Annual General Meeting of 2017, in accordance with the proposal by the Board.
RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation® treatment planning system to clinics all over the world. In addition, RaySearch’s products are distributed through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the company is listed in the Mid Cap segment on Nasdaq Stockholm.
For more information about RaySearch, visit www.raysearchlabs.com.
For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00